Abstract
Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Current Pharmaceutical Design
Title:Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Volume: 20 Issue: 14
Author(s): Seiji Ueda, Sho-ichi Yamagishi, Miyuki Yokoro and Seiya Okuda
Affiliation:
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Abstract: Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Export Options
About this article
Cite this article as:
Ueda Seiji, Yamagishi Sho-ichi, Yokoro Miyuki and Okuda Seiya, Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990480
DOI https://dx.doi.org/10.2174/13816128113199990480 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology Controversial Issues of Abortion License According to Religious and Jurisprudential Laws in Iran: A Systematic Review
Current Women`s Health Reviews Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities
Current Drug Targets - Inflammation & Allergy Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial: Natural Products as the Integral Part of the Therapy?
Current Pharmaceutical Design Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design The Factors Associated with the Length of the Third Stage of Labour: A Descriptive-Analytical Study
Current Women`s Health Reviews Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editor
Current Clinical Pharmacology Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine